Hemab Therapeutics Holdings, Inc. COAG
$25.11
▼ -7.28% 24H
About
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing antibody-based therapies for rare bleeding and thrombotic disorders. The company pioneers preventative treatments and functional cures targeting conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and Von W…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees59
TickerCOAG
Statistics
Market Cap$1.11B
Revenue (TTM)$0
Net Income-$63.9M
Net Margin—
EPS$-2.33
P/E-11.52
P/S—
P/B-5.97
EV/EBITDA-16.78
ROE-47.0%
Dividend Yield—
Price$25.11
Data: Twelve Data · Revenue = mcap / P/S